Research results posted in Lancet are very promising.
Patient group ingesting peanut protein along with probiotics showed the majority of patients were able to tolerate peanuts vs placebo group.
Another step in the right direction to bringing such therapies to our patients soon.
Dupixent, humanized monoclonal antibody, anti-IL-4, anti-IL13, is now available for the treatment of poorly controlled moderate to severe Atopic dermatitis/eczema in patients ages 18 years and older. Studies are under way for patients under 18 years of age.
It is a small injection under the skin every 2 week.
Contact our office for an appointment if you are interested in finally getting her eczema under control.
Recall of Ventolin (Albuterol) by GSK. If your Albuterol is name brand Ventolin then please check to make sure it is not recalled. The affected lot numbers are 6ZP0003, 6ZP9944 and 6ZP9848. Contact GSK’s customer service center at 1-888-825-5249 with questions.
There has been a recall of Epipen and Epipen Jr.
These are pens that expire in April, May, September and October.
Please check your pens at www.mylan.com/epipenrecall
Xolair is approved down to the age of 12 years old for the treatment of Chronic Idiopathic Urticaria (Chronic Hives). So if taking antihistamines is not providing complete relief or the side effects of antihistamines is too much to handle then this may the relief you are looking for. It’s a once a month injection under your skin (on the back of your arms). It’s a unique treatment given by your allergist.
Starting January 2017, we will be extending Tuesday afternoon shot hours from ending at 4:30pm til 4:55 pm by appt. Any patient coming in after 4:30pm should call the office ahead of time and make an appointment.
For infants under the age of 12months, if they are at high risk (+family history of peanut allergy; eczema, allergies), we are offering early introduction protocol in order to prevent them from developing a peanut allergy.
Based on the LEAP Study, regular feeding of peanut protein to children at high risk can significantly reduce the development of peanut allergy.
Make an appt for your at risk infant to be evaluated for a peanut allergy, prior to starting the introduction.
For our patients who liked the Auvi Q, it is set to return to the market February 14, 2017 and will be free to most patients with commercial insurance.
Call our office to request a prescription. If you have not been seen in the past 12 months then schedule an appointment asap.
New peanut study is about to begin at the Johns Hopkins and are enrolling adult (18 yrs to 50 yrs old) patients only with peanut allergy. If interested,contact Kim Mudd at KMudd2@jhmi.edu
In phase 3 trials is the new peanut patch therapy. We are closely following its develop as it appears that it may be available to prescribe in the next few years. We are still awaiting for guidelines for this new therapy.